Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression

Saby George, Robert J. Motzer, Hans J. Hammers, Bruce G. Redman, Timothy M. Kuzel, Scott S. Tykodi, Elizabeth R. Plimack, Joel Jiang, Ian M. Waxman, Brian I. Rini

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

IMPORTANCE Response patterns with immunotherapymay differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE To evaluate the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond investigator-assessed first progression in patients with metastatic renal cell carcinoma (mRCC). DESIGN, SETTING, AND PARTICIPANTS Subgroup analysis of a blinded, randomized, multicenter, phase 2 dose-ranging trial initiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic therapy. Data cutoffs for this subgroup analysis were May 15, 2013, for progression-free survival and objective response rate and March 5, 2014, for overall survival and duration of response. In this analysis, patients treated beyond first progression received their last dose of nivolumab more than 6 weeks after RECIST-defined progression, and patients not treated beyond first progression discontinued nivolumab before or at RECIST-defined progression. INTERVENTIONS Nivolumab 0.3, 2, or 10mg/kg intravenously every 3 weeks. MAIN OUTCOMES AND MEASURES Safety and efficacy of nivolumab treatment. RESULTS Of 168 patients (median [range] age, 61 [37-81] years; 72%male) randomized to nivolumab, 154 experienced progression (36 were treated beyond first progression, 26 were treated beyond first progression for 6 weeks, and 92 were not treated beyond first progression), 13 were treated and did not experience progression, and 1 was not treated. Prior to first progression, the RECIST-defined objective response rate was 14%(5 patients) and 16%(15 patients), and median progression-free survival was 4.2 (95%CI, 2.8-5.5) and 2.6 (95%CI, 1.5-3.9) months in patients treated and not treated beyond progression, respectively. Following initial progression, 25 (69%) patients treated beyond progression experienced subsequent tumor reduction or stabilization in target lesion size. The incidence of treatment-related adverse events was higher in patients treated beyond progression (n = 29 [81%]) vs those not treated beyond progression (n = 61 [66%]); however, after adjusting for length of treatment exposure, incidence was lower in patients treated beyond progression (322.9 vs 518.7 incidence rate/100 patient-years for patients treated vs not treated beyond progression). CONCLUSIONS AND RELEVANCE In this subgroup analysis, a proportion of patients who continued treatment beyond RECIST-defined first progression demonstrated sustained reductions in tumor burden or stabilization in the size of target lesions, with an acceptable safety profile. Further analysis will help define the clinical benefit for patients with mRCC treated with nivolumab beyond progression.

Original languageEnglish (US)
Pages (from-to)1179-1186
Number of pages8
JournalJAMA oncology
Volume2
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Renal Cell Carcinoma
Safety
nivolumab
Disease-Free Survival
Incidence
Therapeutics
Tumor Burden
Immunotherapy
Cell Death

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression. / George, Saby; Motzer, Robert J.; Hammers, Hans J.; Redman, Bruce G.; Kuzel, Timothy M.; Tykodi, Scott S.; Plimack, Elizabeth R.; Jiang, Joel; Waxman, Ian M.; Rini, Brian I.

In: JAMA oncology, Vol. 2, No. 9, 01.09.2016, p. 1179-1186.

Research output: Contribution to journalArticle

George, S, Motzer, RJ, Hammers, HJ, Redman, BG, Kuzel, TM, Tykodi, SS, Plimack, ER, Jiang, J, Waxman, IM & Rini, BI 2016, 'Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression', JAMA oncology, vol. 2, no. 9, pp. 1179-1186. https://doi.org/10.1001/jamaoncol.2016.0775
George, Saby ; Motzer, Robert J. ; Hammers, Hans J. ; Redman, Bruce G. ; Kuzel, Timothy M. ; Tykodi, Scott S. ; Plimack, Elizabeth R. ; Jiang, Joel ; Waxman, Ian M. ; Rini, Brian I. / Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression. In: JAMA oncology. 2016 ; Vol. 2, No. 9. pp. 1179-1186.
@article{baaeddef6ed7424693f8662703feaa68,
title = "Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression",
abstract = "IMPORTANCE Response patterns with immunotherapymay differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE To evaluate the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond investigator-assessed first progression in patients with metastatic renal cell carcinoma (mRCC). DESIGN, SETTING, AND PARTICIPANTS Subgroup analysis of a blinded, randomized, multicenter, phase 2 dose-ranging trial initiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic therapy. Data cutoffs for this subgroup analysis were May 15, 2013, for progression-free survival and objective response rate and March 5, 2014, for overall survival and duration of response. In this analysis, patients treated beyond first progression received their last dose of nivolumab more than 6 weeks after RECIST-defined progression, and patients not treated beyond first progression discontinued nivolumab before or at RECIST-defined progression. INTERVENTIONS Nivolumab 0.3, 2, or 10mg/kg intravenously every 3 weeks. MAIN OUTCOMES AND MEASURES Safety and efficacy of nivolumab treatment. RESULTS Of 168 patients (median [range] age, 61 [37-81] years; 72{\%}male) randomized to nivolumab, 154 experienced progression (36 were treated beyond first progression, 26 were treated beyond first progression for 6 weeks, and 92 were not treated beyond first progression), 13 were treated and did not experience progression, and 1 was not treated. Prior to first progression, the RECIST-defined objective response rate was 14{\%}(5 patients) and 16{\%}(15 patients), and median progression-free survival was 4.2 (95{\%}CI, 2.8-5.5) and 2.6 (95{\%}CI, 1.5-3.9) months in patients treated and not treated beyond progression, respectively. Following initial progression, 25 (69{\%}) patients treated beyond progression experienced subsequent tumor reduction or stabilization in target lesion size. The incidence of treatment-related adverse events was higher in patients treated beyond progression (n = 29 [81{\%}]) vs those not treated beyond progression (n = 61 [66{\%}]); however, after adjusting for length of treatment exposure, incidence was lower in patients treated beyond progression (322.9 vs 518.7 incidence rate/100 patient-years for patients treated vs not treated beyond progression). CONCLUSIONS AND RELEVANCE In this subgroup analysis, a proportion of patients who continued treatment beyond RECIST-defined first progression demonstrated sustained reductions in tumor burden or stabilization in the size of target lesions, with an acceptable safety profile. Further analysis will help define the clinical benefit for patients with mRCC treated with nivolumab beyond progression.",
author = "Saby George and Motzer, {Robert J.} and Hammers, {Hans J.} and Redman, {Bruce G.} and Kuzel, {Timothy M.} and Tykodi, {Scott S.} and Plimack, {Elizabeth R.} and Joel Jiang and Waxman, {Ian M.} and Rini, {Brian I.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1001/jamaoncol.2016.0775",
language = "English (US)",
volume = "2",
pages = "1179--1186",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression

AU - George, Saby

AU - Motzer, Robert J.

AU - Hammers, Hans J.

AU - Redman, Bruce G.

AU - Kuzel, Timothy M.

AU - Tykodi, Scott S.

AU - Plimack, Elizabeth R.

AU - Jiang, Joel

AU - Waxman, Ian M.

AU - Rini, Brian I.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - IMPORTANCE Response patterns with immunotherapymay differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE To evaluate the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond investigator-assessed first progression in patients with metastatic renal cell carcinoma (mRCC). DESIGN, SETTING, AND PARTICIPANTS Subgroup analysis of a blinded, randomized, multicenter, phase 2 dose-ranging trial initiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic therapy. Data cutoffs for this subgroup analysis were May 15, 2013, for progression-free survival and objective response rate and March 5, 2014, for overall survival and duration of response. In this analysis, patients treated beyond first progression received their last dose of nivolumab more than 6 weeks after RECIST-defined progression, and patients not treated beyond first progression discontinued nivolumab before or at RECIST-defined progression. INTERVENTIONS Nivolumab 0.3, 2, or 10mg/kg intravenously every 3 weeks. MAIN OUTCOMES AND MEASURES Safety and efficacy of nivolumab treatment. RESULTS Of 168 patients (median [range] age, 61 [37-81] years; 72%male) randomized to nivolumab, 154 experienced progression (36 were treated beyond first progression, 26 were treated beyond first progression for 6 weeks, and 92 were not treated beyond first progression), 13 were treated and did not experience progression, and 1 was not treated. Prior to first progression, the RECIST-defined objective response rate was 14%(5 patients) and 16%(15 patients), and median progression-free survival was 4.2 (95%CI, 2.8-5.5) and 2.6 (95%CI, 1.5-3.9) months in patients treated and not treated beyond progression, respectively. Following initial progression, 25 (69%) patients treated beyond progression experienced subsequent tumor reduction or stabilization in target lesion size. The incidence of treatment-related adverse events was higher in patients treated beyond progression (n = 29 [81%]) vs those not treated beyond progression (n = 61 [66%]); however, after adjusting for length of treatment exposure, incidence was lower in patients treated beyond progression (322.9 vs 518.7 incidence rate/100 patient-years for patients treated vs not treated beyond progression). CONCLUSIONS AND RELEVANCE In this subgroup analysis, a proportion of patients who continued treatment beyond RECIST-defined first progression demonstrated sustained reductions in tumor burden or stabilization in the size of target lesions, with an acceptable safety profile. Further analysis will help define the clinical benefit for patients with mRCC treated with nivolumab beyond progression.

AB - IMPORTANCE Response patterns with immunotherapymay differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE To evaluate the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond investigator-assessed first progression in patients with metastatic renal cell carcinoma (mRCC). DESIGN, SETTING, AND PARTICIPANTS Subgroup analysis of a blinded, randomized, multicenter, phase 2 dose-ranging trial initiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic therapy. Data cutoffs for this subgroup analysis were May 15, 2013, for progression-free survival and objective response rate and March 5, 2014, for overall survival and duration of response. In this analysis, patients treated beyond first progression received their last dose of nivolumab more than 6 weeks after RECIST-defined progression, and patients not treated beyond first progression discontinued nivolumab before or at RECIST-defined progression. INTERVENTIONS Nivolumab 0.3, 2, or 10mg/kg intravenously every 3 weeks. MAIN OUTCOMES AND MEASURES Safety and efficacy of nivolumab treatment. RESULTS Of 168 patients (median [range] age, 61 [37-81] years; 72%male) randomized to nivolumab, 154 experienced progression (36 were treated beyond first progression, 26 were treated beyond first progression for 6 weeks, and 92 were not treated beyond first progression), 13 were treated and did not experience progression, and 1 was not treated. Prior to first progression, the RECIST-defined objective response rate was 14%(5 patients) and 16%(15 patients), and median progression-free survival was 4.2 (95%CI, 2.8-5.5) and 2.6 (95%CI, 1.5-3.9) months in patients treated and not treated beyond progression, respectively. Following initial progression, 25 (69%) patients treated beyond progression experienced subsequent tumor reduction or stabilization in target lesion size. The incidence of treatment-related adverse events was higher in patients treated beyond progression (n = 29 [81%]) vs those not treated beyond progression (n = 61 [66%]); however, after adjusting for length of treatment exposure, incidence was lower in patients treated beyond progression (322.9 vs 518.7 incidence rate/100 patient-years for patients treated vs not treated beyond progression). CONCLUSIONS AND RELEVANCE In this subgroup analysis, a proportion of patients who continued treatment beyond RECIST-defined first progression demonstrated sustained reductions in tumor burden or stabilization in the size of target lesions, with an acceptable safety profile. Further analysis will help define the clinical benefit for patients with mRCC treated with nivolumab beyond progression.

UR - http://www.scopus.com/inward/record.url?scp=85010416862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010416862&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2016.0775

DO - 10.1001/jamaoncol.2016.0775

M3 - Article

C2 - 27243803

AN - SCOPUS:85010416862

VL - 2

SP - 1179

EP - 1186

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 9

ER -